On a spree, Astellas bags a next-gen, Parker-backed CAR-T platform with $665M buyout deal
A little more than a year after the Parker Institute swooped in with an equity investment for South San Francisco-based Xyphos Biosciences’ second-gen CAR-T platform, Astellas has stepped in with a $665 million deal to buy the whole thing.
Tokyo-based Astellas — which anted up $120 million in cash to close the deal — was attracted to a bispecific approach that promises to be both safer and more effective than the pioneers now on the market.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 102,100+ biopharma pros reading Endpoints daily — and it's free.